ArticleTheranostics2013
ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages.
Article in Theranostics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 127 citations in OpenAlex.
- Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges.Journal of nanobiotechnology · 2025Review
- Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy.Molecular imaging and biology · 2025Review
- Bioresponsive engineered nanoparticles for immunomodulation.BMC medicine · 2025Review
- Nano-therapeutics targeting the macrophage-based microenvironment in the treatment of atherosclerosis.Journal of translational medicine · 2025Review
- Recent progress in ROS-responsive biomaterials for the diagnosis and treatment of cardiovascular diseases.Theranostics · 2025Review
- The Landscape of Smart Biomaterial-Based Hydrogen Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.Journal of nanobiotechnology · 2024Article
- Smart stimuli-responsive drug delivery systems in spotlight of COVID-19.Asian journal of pharmaceutical sciences · 2023Review
- GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease.Bioactive materials · 2023Article
- Recent Advances for Dynamic-Based Therapy of Atherosclerosis.International journal of nanomedicine · 2023Review
- Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms.Frontiers in bioengineering and biotechnology · 2023Review
- Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.Bioactive materials · 2023Article
- ROS- and pH-Responsive Polydopamine Functionalized TiNanomaterials (Basel, Switzerland) · 2022Article
- Advances in imaging and treatment of atherosclerosis based on organic nanoparticles.APL bioengineering · 2022Review
- ROS-Responsive Glycopolymeric Nanoparticles for Enhanced Drug Delivery to Macrophages.Macromolecular bioscience · 2022Article
- Potentiating hypoxic microenvironment for antibiotic activation by photodynamic therapy to combat bacterial biofilm infections.Nature communications · 2022Article
- Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Extracellular vesicles as a novel photosensitive drug delivery system for enhanced photodynamic therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Recent Advances in ROS-Sensitive Nano-Formulations for Atherosclerosis Applications.Pharmaceutics · 2021Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optical properties of macrophage-targeted theranostic nanoparticles (MacTNP) prepared from a Chlorin e6 (Ce6)-hyaluronic acid (HA) conjugate can be activated by reactive oxygen species (ROS) in macrophage cells. MacTNP are nonfluorescent and nonphototoxic in their native state. However, when treated with ROS, especially peroxynitrite, they become highly fluorescent and phototoxic. In vitro cell studies show that MacTNP emit near-infrared (NIR) fluorescence inside activated macrophages. The NIR fluorescence is quenched in the extracellular environment. MacTNP are nontoxic in macrophages up to a Ce6 concentration of 10 μM in the absence of light. However, MacTNP become phototoxic upon illumination in a light dose-dependent manner. In particular, significantly higher phototoxic effect is observed in the activated macrophage cells compared to human dermal fibroblasts and non-activated macrophages. The ROS-responsive MacTNP, with their high target-to-background ratio, may have a significant potential in selective NIR fluorescence imaging and in subsequent photodynamic therapy of atherosclerosis with minimum side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.